BioMarin Pharma to Launch Convertible Notes Offerings

BioMarin Pharmaceutical (NASDAQ: BMRN  ) has concocted a formula to raise capital from the markets. The company announced it will float a pair of $300 million senior subordinated convertible notes offerings. The first will mature in 2018, and the second in 2020. Additionally, BioMarin said it expects to grant the offering's underwriters an option to purchase up to an additional $70 million worth of the notes. 

The company will use its share of the issue's proceeds for "general corporate purposes," including working capital, and research and development activities.

The joint book-running managers of the offering are Bank of America unit Merrill Lynch, Goldman Sachs, JPMorgan Chase's (NYSE: JPM  ) J.P. Morgan, and Morgan Stanley (NYSE: MS  ) .

BioMarin has just over 140 million shares outstanding, and its stock most recently closed at $67.25 per share.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2674390, ~/Articles/ArticleHandler.aspx, 11/28/2014 8:24:16 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement